Psychopharmacology

, Volume 193, Issue 2, pp 159–170 | Cite as

Yawning and hypothermia in rats: effects of dopamine D3 and D2 agonists and antagonists

  • Gregory T. Collins
  • Amy Hauck Newman
  • Peter Grundt
  • Kenner C. Rice
  • Stephen M. Husbands
  • Cédric Chauvignac
  • Jianyong Chen
  • Shaomeng Wang
  • James H. Woods
Original Investigation

Abstract

Rationale

Identification of behaviors specifically mediated by the dopamine D2 and D3 receptors would allow for the determination of in vivo receptor selectivity and aide the development of novel therapeutics for dopamine-related diseases.

Objectives

These studies were aimed at evaluating the specific receptors involved in the mediation of D2/D3 agonist-induced yawning and hypothermia.

Materials and methods

The relative potencies of a series of D2-like agonists to produce yawning and hypothermia were determined. The ability of D3-selective and D2-selective antagonists to inhibit the induction of yawning and hypothermia were assessed and a series of D2/D3 antagonists were characterized with respect to their ability to alter yawning induced by a low and high dose of PD-128,907 and sumanirole-induced hypothermia.

Results

D3-preferring agonists induced yawning at lower doses than those required to induce hypothermia and the D2-preferring agonist, sumanirole, induced hypothermia at lower doses than were necessary to induce yawning. The rank order of D3 selectivity was pramipexole > PD-128,907 = 7-OH-DPAT = quinpirole = quinelorane > apomorphine = U91356A. Sumanirole had only D2 agonist effects. PG01037, SB-277011A, and U99194 were all D3-selective antagonists, whereas haloperidol and L-741,626 were D2-selective antagonists and nafadotride’s profile of action was more similar to the D2 antagonists than to the D3 antagonists.

Conclusions

D3 and D2 receptors have specific roles in the mediation of yawning and hypothermia, respectively, and the analysis of these effects allow inferences to be made regarding the selectivity of D2/D3 agonists and antagonists with respect to their actions at D2 and D3 receptors.

Keywords

D2 receptors D3 receptors Yawning Hypothermia Pramipexole Quinpirole PG01037 SB-277011A Agonists Antagonists 

Notes

Acknowledgement

This research was supported by the USPHS NIDA grants DA 020669, DA 019322, F013771 and the NIDA-IRP. We acknowledge with appreciation the technical assistance of Davina Barron and the editorial assistance of Roger Sunahara and Gail Winger.

References

  1. Andreoli M, Tessari M, Pilla M, Valerio E, Hagan JJ, Heidbreder CA (2003) Selective antagonism at dopamine D3 receptors prevents nicotine-triggered relapse to nicotine-seeking behavior. Neuropsychopharmacology 28(7):1272–1280PubMedCrossRefGoogle Scholar
  2. Argiolas A, Melis MR (1998) The neuropharmacology of yawning. Eur J Pharmacol 343(1):1–16PubMedCrossRefGoogle Scholar
  3. Audinot V, Newman-Tancredi A, Gobert A, Rivet JM, Brocco M, Lejeune F, Gluck L, Desposte I, Bervoets K, Dekeyne A, Millan MJ (1998) A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (1)-S 14297, nafadotride, GR 103,691, and U 99194. J Pharmacol Exp Ther 287:187–197PubMedGoogle Scholar
  4. Boulay D, Depoortere R, Perrault G, Borrelli E, Sanger DJ (1999a) Dopamine D2 receptor knock-out mice are insensitive to the hypolocomotor and hypothermic effects of dopamine D2/D3 receptor agonists. Neuropharmacology 38(9):1389–1396PubMedCrossRefGoogle Scholar
  5. Boulay D, Depoortere R, Rostene W, Perrault G, Sanger DJ (1999b) Dopamine D3 receptor agonists produce similar decreases in body temperature and locomotor activity in D3 knock-out and wild-type mice. Neuropharmacology 38(4):555–565PubMedCrossRefGoogle Scholar
  6. Brioni JD, Moreland RB, Cowart M, Hsieh GC, Stewart AO, Hedlund P, Donnelly-Roberts DL, Nakane M, Lynch JJ 3rd, Kolasa T, Polakowski JS, Osinski MA, Marsh K, Andersson KE, Sullivan JP (2004) Activation of dopamine D4 receptors by ABT-724 induces penile erection in rats. Proc Natl Acad Sci U S A 101(17):6758–6763PubMedCrossRefGoogle Scholar
  7. Cervo L, Cocco A, Petrella C, Heidbreder CA (2007) Selective antagonism at dopamine D3 receptors attenuates cocaine-seeking behaviour in the rat. Int J Neuropsychopharmacol 10(2):167–181PubMedCrossRefGoogle Scholar
  8. Chaperon F, Tricklebank MD, Unger L, Neijt HC (2003) Evidence for regulation of body temperature in rats by dopamine D2 receptor and possible influence of D1 but not D3 and D4 receptors. Neuropharmacology 44(8):1047–1053PubMedCrossRefGoogle Scholar
  9. Chio CL, Lajiness ME, Huff RM (1994) Activation of heterologously expressed D3 dopamine receptors: comparison with D2 dopamine receptors. Mol Pharmacol 45(1):51–60PubMedGoogle Scholar
  10. Collins GT, Witkin JM, Newman AH, Svensson KA, Grundt P, Cao J, Woods JH (2005) Dopamine agonist-induced yawning in rats: a dopamine D3 receptor-mediated behavior. J Pharmacol Exp Ther 314(1):310–319PubMedCrossRefGoogle Scholar
  11. Depoortere R, Perrault G, Sanger DJ (1996) Behavioural effects in the rat of the putative dopamine D3 receptor agonist 7-OH-DPAT: comparison with quinpirole and apomorphine. Psychopharmacology (Berl) 124(3):231–240CrossRefGoogle Scholar
  12. Di Ciano P, Underwood RJ, Hagan JJ, Everitt BJ (2003) Attenuation of cue-controlled cocaine-seeking by a selective D3 dopamine receptor antagonist SB-277011-A. Neuropsychopharmacology 28(2):329–338PubMedCrossRefGoogle Scholar
  13. Enguehard-Gueiffier C, Hubner H, El Hakmaoui A, Allouchi H, Gmeiner P, Argiolas A, Melis MR, Gueiffier A (2006) 2-[(4-phenylpiperazin-1-yl)methyl]imidazo(di)azines as selective D4-ligands. Induction of penile erection by 2-[4-(2-methoxyphenyl)piperazin-1-ylmethyl]imidazo[1,2-a]pyridine (PIP3EA), a potent and selective D4 partial agonist. J Med Chem 49(13):3938–3947PubMedCrossRefGoogle Scholar
  14. Faunt JE, Crocker AD (1987) The effects of selective dopamine receptor agonists and antagonists on body temperature in rats. Eur J Pharmacol 133(3):243–247PubMedCrossRefGoogle Scholar
  15. Gerlach M, Double K, Arzberger T, Leblhuber F, Tatschner T, Riederer P (2003) Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum. J Neural Transm 110(10):1119–1127PubMedCrossRefGoogle Scholar
  16. Gilbert JG, Newman AH, Gardner EL, Ashby CR Jr, Heidbreder CA, Pak AC, Peng XQ, Xi ZX (2005) Acute administration of SB-277011A, NGB 2904, or BP 897 inhibits cocaine cue-induced reinstatement of drug-seeking behavior in rats: role of dopamine D3 receptors. Synapse 57(1):17–28PubMedCrossRefGoogle Scholar
  17. Goudie AJ, Baker LE, Smith JA, Prus AJ, Svensson KA, Cortes-Burgos LA, Wong EH, Haadsma-Svensson S (2001) Common discriminative stimulus properties in rats of muscarinic antagonists, clozapine and the D3 preferring antagonist PNU-99194a:an analysis of possible mechanisms. Behav Pharmacol 12(5):303–315PubMedGoogle Scholar
  18. Grundt P, Carlson EE, Cao J, Bennett CJ, McElveen E, Taylor M, Luedtke RR, Newman AH (2005) Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor. J Med Chem 48(3):839–848PubMedCrossRefGoogle Scholar
  19. Gurevich EV, Joyce JN (1999) Distribution of dopamine D3 receptor expressing neurons in the human forebrain: comparison with D2 receptor expressing neurons. Neuropsychopharmacology 20(1):60–80PubMedCrossRefGoogle Scholar
  20. Happe S, Trenkwalder C (2004) Role of dopamine receptor agonists in the treatment of restless legs syndrome. CNS Drugs 18(1):27–36PubMedCrossRefGoogle Scholar
  21. Heidbreder CA, Gardner EL, Xi ZX, Thanos PK, Mugnaini M, Hagan JJ, Ashby CR Jr (2005) The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence. Brain Res Brain Res Rev 49(1):77–105PubMedCrossRefGoogle Scholar
  22. Heier RF, Dolak LA, Duncan JN, Hyslop DK, Lipton MF, Martin IJ, Mauragis MA, Piercey MF, Nichols NF, Schreur PJ, Smith MW, Moon MW (1997) Synthesis and biological activities of (R)-5,6-dihydro-N,N-dimethyl-4H-imidazo[4,5,1-ij]quinolin-5-amine and its metabolites. J Med Chem 40(5):639–646PubMedCrossRefGoogle Scholar
  23. Holmgren B, Urba-Holmgren R (1980) Interaction of cholinergic and dopaminergic influences on yawning behavior. Acta Neurobiol Exp (Wars) 40(3):633–642Google Scholar
  24. Joyce JN (2001) Dopamine D3 receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs. Pharmacol Ther 90(2–3):231–259PubMedCrossRefGoogle Scholar
  25. Leriche L, Schwartz JC, Sokoloff P (2003) The dopamine D3 receptor mediates locomotor hyperactivity induced by NMDA receptor blockade. Neuropharmacology 45(2):174–181PubMedCrossRefGoogle Scholar
  26. Levesque D, Diaz J, Pilon C, Martres MP, Giros B, Souil E, Schott D, Morgat JL, Schwartz JC, Sokoloff P (1992) Identification, characterization, and localization of the dopamine D3 receptor in rat brain using 7-[3H]hydroxy-N,N-di-n-propyl-2-aminotetralin. Proc Natl Acad Sci USA 89(17):8155–8159PubMedCrossRefGoogle Scholar
  27. McCall RB, Lookingland KJ, Bedard PJ, Huff RM (2005) Sumanirole, a highly dopamine D2-selective receptor agonist: in vitro and in vivo pharmacological characterization and efficacy in animal models of Parkinson’s disease. J Pharmacol Exp Ther 314(3):1248–1256PubMedCrossRefGoogle Scholar
  28. Mierau J, Schneider FJ, Ensinger HA, Chio CL, Lajiness ME, Huff RM (1995) Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors. Eur J Pharmacol 290(1):29–36PubMedCrossRefGoogle Scholar
  29. Millan MJ, Peglion JL, Vian J, Rivet JM, Brocco M, Gobert A, Newman-Tancredi A, Dacquet C, Bervoets K, Girardon S, Jacques V, Chaput C, Audinot V (1995) Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: 1. Activation of postsynaptic D3 receptors mediates hypothermia, whereas blockade of D2 receptors elicits prolactin secretion and catalepsy. J Pharmacol Exp Ther 275(2):885–898PubMedGoogle Scholar
  30. Millan MJ, Dekeyne A, Rivet JM, Dubuffet T, Lavielle G, Brocco M (2000) S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: II. Functional and behavioral profile compared with GR218,231 and L741,626. J Pharmacol Exp Ther 293(3):1063–1073PubMedGoogle Scholar
  31. Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A (2002) Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 303(2):791–804PubMedCrossRefGoogle Scholar
  32. Mogilnicka E, Klimek V (1977) Drugs affecting dopamine neurons and yawning behavior. Pharmacol Biochem Behav 7(4):303–305PubMedCrossRefGoogle Scholar
  33. Newman AH, Grundt P, Nader MA (2005) Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents. J Med Chem 48(11):3663–3679PubMedCrossRefGoogle Scholar
  34. Piercey MF, Moon MW, Sethy VH, Schreur PJ, Smith MW, Tang AH, Von Voigtlander PF (1996) Pharmacology of U-91356A, an agonist for the dopamine D2 receptor subtype. Eur J Pharmacol 317(1):29–38PubMedCrossRefGoogle Scholar
  35. Pugsley TA, Davis MD, Akunne HC, MacKenzie RG, Shih YH, Damsma G, Wikstrom H, Whetzel SZ, Georgic LM, Cooke LW, Demattos SB, Corbin AE, Glase SA, Wise LD, Dijkstra D, Heffner TG (1995) Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907. J Pharmacol Exp Ther 275(3):1355–1366PubMedGoogle Scholar
  36. Reavill C, Taylor SG, Wood MD, Ashmeade T, Austin NE, Avenell KY, Boyfield I, Branch CL, Cilia J, Coldwell MC, Hadley MS, Hunter AJ, Jeffrey P, Jewitt F, Johnson CN, Jones DN, Medhurst AD, Middlemiss DN, Nash DJ, Riley GJ, Routledge C, Stemp G, Thewlis KM, Trail B, Vong AK, Hagan JJ (2000) Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A. J Pharmacol Exp Ther 294(3):1154–1165PubMedGoogle Scholar
  37. Richtand NM, Logue AD, Welge JA, Perdiue J, Tubbs LJ, Spitzer RH, Sethuraman G, Geracioti TD (2000) The dopamine D3 receptor antagonist nafadotride inhibits development of locomotor sensitization to amphetamine. Brain Res 867(1–2):239–242PubMedCrossRefGoogle Scholar
  38. Sautel F, Griffon N, Levesque D, Pilon C, Schwartz JC, Sokoloff P (1995) A functional test identifies dopamine agonists selective for D3 versus D2 receptors. Neuroreport 6(2):329–332PubMedCrossRefGoogle Scholar
  39. Seeman P, Ko F, Willeit M, McCormick P, Ginovart N (2005) Antiparkinson concentrations of pramipexole and PHNO occupy dopamine D2(high) and D3(high) receptors. Synapse 58(2):122–128PubMedCrossRefGoogle Scholar
  40. Smith HP, Nichols DE, Mailman RB, Lawler CP (1997) Locomotor inhibition, yawning and vacuous chewing induced by a novel dopamine D2 post-synaptic receptor agonist. Eur J Pharmacol 323(1):27–36PubMedCrossRefGoogle Scholar
  41. Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC (1990) Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347(6289):146–151PubMedCrossRefGoogle Scholar
  42. Stancampiano R, Melis MR, Argiolas A (1994) Penile erection and yawning induced by 5-HT1C receptor agonists in male rats: relationship with dopaminergic and oxytocinergic transmission. Eur J Pharmacol 261(1–2):149–155PubMedCrossRefGoogle Scholar
  43. Stemp G, Ashmeade T, Branch CL, Hadley MS, Hunter AJ, Johnson CN, Nash DJ, Thewlis KM, Vong AK, Austin NE, Jeffrey P, Avenell KY, Boyfield I, Hagan JJ, Middlemiss DN, Reavill C, Riley GJ, Routledge C, Wood M (2000) Design and synthesis of trans-N-[4-[2-(6-cyano-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl]cyclohexyl]-4-quinolinecarboxamide (SB-277011): a potent and selective dopamine D(3) receptor antagonist with high oral bioavailability and CNS penetration in the rat. J Med Chem 43(9):1878–1885PubMedCrossRefGoogle Scholar
  44. Urba-Holmgren R, Gonzalez RM, Holmgren B (1977) Is yawning a cholinergic response? Nature 267(5608):261–262PubMedCrossRefGoogle Scholar
  45. Vangveravong S, McElveen E, Taylor M, Xu J, Tu Z, Luedtke RR, Mach RH (2006) Synthesis and characterization of selective dopamine D2 receptor antagonists. Bioorg Med Chem 14(3):815–825PubMedCrossRefGoogle Scholar
  46. Xi ZX, Gilbert J, Campos AC, Kline N, Ashby CR Jr, Hagan JJ, Heidbreder CA, Gardner EL (2004) Blockade of mesolimbic dopamine D3 receptors inhibits stress-induced reinstatement of cocaine-seeking in rats. Psychopharmacology (Berl) 176(1):57–65CrossRefGoogle Scholar
  47. Xi ZX, Gilbert JG, Pak AC, Ashby CR Jr, Heidbreder CA, Gardner EL (2005) Selective dopamine D3 receptor antagonism by SB-277011A attenuates cocaine reinforcement as assessed by progressive-ratio and variable–cost–variable–payoff fixed-ratio cocaine self-administration in rats. Eur J Neurosci 21(12):3427–3438PubMedCrossRefGoogle Scholar
  48. Yamada K, Furukawa T (1980) Direct evidence for involvement of dopaminergic inhibition and cholinergic activation in yawning. Psychopharmacology (Berl) 67(1):39–43CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Gregory T. Collins
    • 1
  • Amy Hauck Newman
    • 2
  • Peter Grundt
    • 2
  • Kenner C. Rice
    • 3
  • Stephen M. Husbands
    • 4
  • Cédric Chauvignac
    • 4
  • Jianyong Chen
    • 5
  • Shaomeng Wang
    • 1
    • 5
  • James H. Woods
    • 1
  1. 1.Department of PharmacologyUniversity of Michigan Medical SchoolAnn ArborUSA
  2. 2.Medicinal Chemistry Section, National Institutes on Drug Abuse-Intramural Research ProgramNational Institutes of HealthBaltimoreUSA
  3. 3.Chemical Biology Research Branch, National Institute on Drug Abuse-Intramural Research ProgramNational Institutes of HealthBethesdaUSA
  4. 4.Department of Pharmacy and PharmacologyUniversity of BathBathUK
  5. 5.Departments of Internal Medicine and Medicinal ChemistryUniversity of Michigan Medical SchoolAnn ArborUSA

Personalised recommendations